DENVER, June 08, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announces that the Mydecine R&D team has made groundbreaking advances in psilocybin research with the…


Previous articlePT247 – Julian Vayne – Magic, Prohibition, and New Models for Legality
Next articleAwakn Life Sciences Completes Previously Announced Private Placement For Gross Proceeds Of $8.3 Million